Company news

OSE Immunotherapeutics SA news in 2026

OSE Immunotherapeutics SA's news releases, calls and decks from 2026, newest first.

View company

OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

October 29, 2026

OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

October 28, 2026

OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

October 19, 2026

OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference

October 15, 2026

Informations relatives au nombre total de droits de vote et d’actions composant le capital

October 6, 2026

OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update

September 28, 2026

OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting

September 23, 2026

OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO

September 22, 2026

OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients

September 9, 2026

OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux

September 8, 2026

Informations relatives au nombre total de droits de vote et d’actions composant le capital

September 6, 2026

OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026

August 27, 2026

Informations relatives au nombre total de droits de vote et d’actions composant le capital

August 25, 2026

Informations relatives au nombre total de droits de vote et d’actions composant le capital

July 7, 2026

OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting

June 24, 2026

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting

June 3, 2026

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document

June 3, 2026

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing

May 28, 2026

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

May 22, 2026

OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position

April 30, 2026

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients

April 27, 2026

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

April 23, 2026

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

April 15, 2026

OSE Immunotherapeutics Evolves its Leadership Team

April 14, 2026

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

March 23, 2026

OSE Immunotherapeutics Announces its 2026 Financial Calendar

March 16, 2026

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth

March 10, 2026

OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®

March 2, 2026

OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

February 26, 2026

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab

January 29, 2026

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)

January 21, 2026

Half-Year Report on Liquidity Contract with Invest Securities

January 20, 2026

Decks in 2026